

## PRESS RELEASE

6 May 2025

### DMC Launches Fermented Myo-Inositol, a Cleaner and more Sustainable Alternative, Benefiting Metabolic, Reproductive, and Infant Health markets.

DMC Biotechnologies, a leading U.S.-based biomanufacturer, is pleased to announce the commercial launch of **fermented myo-inositol**. This next-generation ingredient is now available for health-focused brands and formulators seeking high-quality, naturally produced, sustainable solutions, with improved supply resilience.

#### Elevating the Standard Through Fermentation

DMC's **fermentation-derived myo-inositol** is produced through a natural, solvent-free process that ensures superior purity and reduces environmental impact. Traditional chemical synthesis of myo-inositol uses harsh chemical processes, feedstock more susceptible to impurities, and significant energy for refining. Fermented myo-inositol meets the increasing demand from consumers, brands, and formulators for **clean-label, responsibly sourced** ingredients.

"We're proud to introduce a cleaner, more sustainable source of myo-inositol—an essential nutrient that supports glucose management, reproductive health, and infant development," said **Rusty Pittman, VP of Business Development at DMC**. "Fermented myo-inositol is more naturally produced, better for the environment and offers higher assurance of purity and consistent quality – important benefits for all health ingredients. We are particularly grateful to the leading brands that supported this initiative with valuable product insights and early supply commitments."

#### Building a Nutraceutical Portfolio and Sustainable Future

"Myo-inositol marks DMC's entry into the nutraceutical space," said **Jim Flatt, CEO of DMC**. "We're excited to follow it with a second ingredient later this year—the beginning of a broader **portfolio of nutraceutical and cosmetic actives** we are building. These two product introductions are clear examples of DMC's ability to meet the growing market demand for sustainable products in a timely and cost-efficient manner."

This launch is aligned with DMC's mission to deliver naturally produced, cleaner ingredients and sustainable chemicals that **decarbonize and secure supply chains** and do so with **economic viability**.

#### A Critical Nutrient for Human Health

Myo-inositol, a naturally occurring sugar in the human body, plays a key role in cell signaling, insulin response, and neurotransmitter function, making it essential across various life stages and health conditions. With significant growth across key **dietary supplement, infant nutrition, and functional food markets, a naturally produced, cleaner, and sustainable source of myo-inositol is more important than ever.**

Myo-inositol provides clinically proven health and wellness benefits for:

- **Metabolic Health:** Supports insulin signaling and glucose metabolism, aiding in conditions like insulin resistance, type 2 and gestational diabetes, and metabolic syndrome.
- **Reproductive Health:** Used in fertility and women's health formulations to support hormonal balance, ovulation, and egg quality—especially for those with polycystic ovary syndrome (PCOS).
- **Infant Nutrition:** Found naturally in breast milk, myo-inositol is a required ingredient in infant formula and is believed

## PRESS RELEASE

6 May 2025

### About DMC

DMC is a U.S.-based biomanufacturer redefining how the world produces chemicals. Through precision fermentation and synthetic biology, DMC creates sustainable, bio-based alternatives that reduce carbon emissions, enhance ingredient quality, and strengthen global supply chain resilience. The company's proprietary platform, **Dynamic Metabolic Control™**, simplifies biological processes to enable predictable, scalable, and highly efficient fermentation—unlocking a new era of low-impact chemical manufacturing.

[www.dmcbio.com](http://www.dmcbio.com)

### About Capricorn Partners

Capricorn Partners is an independent European manager of venture capital and equity funds, investing in innovative European companies with technology as competitive advantage. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience. Capricorn Partners is managing the venture capital funds Capricorn Sustainable Chemistry Fund, Capricorn Digital Growth Fund, Capricorn ICT Arkiv, Capricorn Health-tech Fund, Capricorn Healthtech Fund II and Capricorn Fusion China Fund. In addition it is the management company of Quest for Growth, quoted on Euronext Brussels, and the investment manager of Quest Cleantech Fund and Quest+, sub-funds of Quest Management SICAV, registered in Luxembourg.

[www.capricorn.be](http://www.capricorn.be)

